Key result
Review outlines contemporary hyperkalemia management in CKD, highlighting RAASi discontinuation, SGLT2i, and novel potassium binders.
Why the study?
Recent advances have emerged in hyperkalemia management, but guidance was needed to navigate drug-induced hyperkalemia from RAASi, newer therapies like SGLT2i and oral potassium binders, and dietary restriction.
Novel potassium binders and SGLT2 inhibitors provide new strategies to manage hyperkalemia, allowing for the continuation of life-saving RAASi therapy in patients with CKD and heart failure.
May enable RAASi continuation with SGLT2i and binders in CKD hyperkalemia; leaves open prospective outcome trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Massicotte‐Azarniouch et al. (2023) conducted a review in Hyperkalemia in chronic kidney disease. Hyperkalemia management strategies (SGLT2i, potassium binders, RAASi continuation) was evaluated. This narrative review discusses contemporary management of hyperkalemia in chronic kidney disease, focusing on RAASi discontinuation, SGLT2 inhibitors, and novel oral potassium binding agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: